Oramed Pharmaceuticals in the news
Oramed Pharmaceuticals Inc, a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, have announced plans to develop a weight loss treatment in the form of an oral Leptin capsule. This follows positive preclinical data and regulatory approval from Israel’s Ministry of Health to conduct human studies. Leptin, also known as the “obesity hormone” is a protein that helps to inhibit hunger and regulate energy balance. According to Grand View Research, the overall obesity market is expected to reach $15.6 billion in 2024. Read the full press release here.
There is more good news for Oramed as the European Patent Office and Canadian Intellectual Property Office have both granted the Company a patent covering their invention of an oral glucagon-like peptide-1 (GLP-1) analog, Exenatide. Oramed’s oral GLP-1 capsule based on the Company’s Protein Oral Delivery (PODTM) technology could significantly increase compliance and become a valuable tool in the treatment of diabetes. The European Patent Office has also granted the Company a patent covering their invention relating to a combination therapy including both insulin and a GLP-1 analog in a single oral capsule. Combination therapies of insulin and GLP-1 analogs have been shown to be highly effective at achieving optimal blood sugar control without an increased risk for hypoglycemia.
Mewburn Ellis partner Joseph Lenthall has been working with Oramed on their European IP portfolio and continues to do so.